Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-11-27
2007-11-27
Allen, Marianne P. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S397000, C530S399000
Reexamination Certificate
active
10455697
ABSTRACT:
Erythropoietin (Epo), a member of the cytokine superfamily, is a pluripotent molecule that is involved in a number of signal transduction pathways that include the stimulation of the production of red blood cells and the protection of the central nervous system from acute injury and ischemia. The invention is the discovery of Epo and the Epo receptor in the peripheral nervous system where it can act as a neuroprotective agent. The invention is also a method of use for the treatment of neuropathic pain and to increase the rate of healing from nerve injury comprising administration of Epo.
REFERENCES:
patent: 5835382 (1998-11-01), Wilson et al.
patent: 6045830 (2000-04-01), Igari et al.
patent: 6221608 (2001-04-01), Middleton et al.
patent: 6310078 (2001-10-01), Connolly et al.
patent: 6319499 (2001-11-01), Elliott
patent: 6333306 (2001-12-01), Lehmann
patent: 6340742 (2002-01-01), Burg et al.
patent: 6489293 (2002-12-01), Sykowski et al.
patent: 2003/0104988 (2003-06-01), Brines et al.
Wells, Additivity of Mutational Effects in Proteins. Biochemistry vol. 29/37:8509-8517 (1990).
Vinik, A. Clinical review: use of antiepileptic drugs in the treatment of painful diabetic neuropathy. The Journal of Clinical Endocrinology and Metabolism 90(8):4936-4945 (2005).
Eastman, Richard C. Neuropathy in Diabetes. Chapter 15 (pp. 339-348) from Diabetes in America. 2ndEdition (1995).
Knowles et al. Painful diabetic neuropathy:assessment and treatment-Clinical. Journal of Diabetes Nursing, pp. 1-9. (Jul.-Aug. 2002).
Veves, A et al. Painful neuropathy and foot ulceration in diabetic patients. Abstract, Diabetes Care 16(8):1187-9 (Aug. 1993).
Tsigos, C et al. Plasma norepinephrine in sensory diabetic polyneuropathy. Abstract, Diabetes Care 16(5):722-7 (May 1993).
Veves, A. et al. Differences in peripheral and autonomic nerve function measurements in painful and painless neuropathy. A clinical study. Abstract, Diabetes Care 17(10):1200-2 (Oct. 1994).
Britland, ST, et al. Acute and remitting painful diabetic polyneuropathy: a comparison of peripheral nerve fibre pathology. Abstract, Pain 48(3):361-70 (Mar. 1992).
Britland, ST et al. Association of painful and painless diabetic polyneuropathy with different patterns of nerve fiber degeneration and regeneration. Abstract, Diabetes 39(8):898-908 (Aug. 1990).
Young, RJ et al. Variable relationship between peripheral somatic and autonomic neuropathy in patients with different syndromes of diabetic polyneuropathy. Abstract, Diabetes 35(2):192-7 (Feb. 1986).
Tsigos, C et al. Discrimination between painful and painless diabetic neuropathy based on testing of large somatic nerve and sympathetic nerve function. Abstract, Diabet. Med. 9(4):359-65 (May 1992).
Fink et al. Small-fiber neuropathy:Answering the burning questions. Science of Aging Knowledge Environment. vol. 2006, Issue 6, p.e7; pp. 1-9 (Mar. 8, 2006).
Brines et al., Erythropoietin crosses the blood-brain barrier to protect against expermental brain injury. Proc.Natl.Acad.Sci.USA 97:10526-10531, 2000.
Campana et al., Prosapeptide activates the MAPK pathway by a G-protein dependent mechanism essential for enhanced sulfatide synthesis by Schwann cell FASEB J. 12:307-314, 1998.
Campana et al., Identification of a neurotrophic sequence in erythropoietin. Int. J. Mol. Med. 1:235-241.1998.
Campana et al., Erythropoietin and erythropoietin receptors in the peripheral nervous system: changes after nerve injury. FASEB J. express article 10.1096. 2001.
Celik et al., Erythropoietin prevents motor neuron apoptosis and neurological disability in experimental spinal cord ischeimic injury. Proc.Natl.Acad.Sci.USA 99:2258-63, 2002.
Digicaylioglu and Lipton, Erythropoietin-mediated neuroprotection invovles cross-talk between Jak2 and Nf-kB signalling cascasesNature 412:641-7, 2001.
Egrie et al., Pharmacokinetics of recombinant human erythropoietin (rHuEpo) administered to hemodialysis patient. Kidney Int., 33:262, 1998.
Ehrenreich et al., Erythropoietin therapy for acute stroke is both safe and beneficial. Mol.Medicine 8:495-505, 2002.
Fisher, Erythropoietin: Physiology and pharmacology update. Exp Biol. Med. 288:1-14, 2003.
Hargreaves et al., New and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32:77-78, 1988.
Igarashi et al., Exogenous tumor necrosis factor-alph mimics nucleus pulposus-induced neuropathology. Spine 25:2975-80, 2000.
Junk et al., Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc.Natl.Acad.Sci.USA 99:10659-64, 2002.
Konishi et al. Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo. Brain.Res. 609:29-35.1993.
MacDougall, Novel erythropoiesis stimulating protein. Semin.Nephrol. 20:375-381, 2000.
Marti et al. neuroprotection and angiogenesis: Dual role of erythropoietin in brain ischemia. New. Physiol. Sci. 15:225-229. 2000.
Masuda et al. Functional erythropoietin receptor of the cells with neural characteristics. J.Biol.Chem. 268:11208-16.1993.
Morishita et al., Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and epo prevents in vitro . . . Neurosci, 76:105-116. 1997.
Sakanaka et al., In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc. Natl. Acad. Sci. USA 95:4635-4640, 1998.
Sirén et al., Erythropoiesis prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc.Natl.Acad.Sci.USA 98:4004-09, 2000.
Wagner R. and Myers RR., Endoneurial injection of TNF-alpha produces neuropathic pain behaviors. Neuroreport 7:2897-901, 1996.
Campana W. Marie
Myers Robert R.
Allen Marianne P.
DeBerry Regina M.
Mandel & Adriano
The Regents of the University of California
LandOfFree
Use of erythropoietin and erythropoietin mimetics for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of erythropoietin and erythropoietin mimetics for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of erythropoietin and erythropoietin mimetics for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3843795